((2-((2-(dimethylamino)ethyl)thio)-acetyl)azanediyl)bis(ethane-2,1-diyl)ditetradecanoate | 1415840-66-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ((2-((2-(dimethylamino)ethyl)thio)-acetyl)azanediyl)bis(ethane-2,1-diyl)ditetradecanoate
• 英文别名: Jqq4KM6mjk；2-[[2-[2-(dimethylamino)ethylsulfanyl]acetyl]-(2-tetradecanoyloxyethyl)amino]ethyl tetradecanoate
• CAS: 1415840-66-2
• 化学式: C₃₈H₇₄N₂O₅S
• 分子量: 671.082
• InChiKey: LYVCKXIOCZNKRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.7
• 重原子数：
  46
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ((2-((2-(dimethylamino)ethyl)thio)-acetyl)azanediyl)bis(ethane-2,1-diyl)ditetradecanoate 在 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 以540 mg的产率得到((2-((2-(dimethylamino)ethyl)sulfonyl)acetyl)azanediyl)bis(ethane-2,1-diyl) ditetradecanoate
  参考文献：
  名称：

  LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS

  摘要：

  该描述针对可用于增强脂质体中治疗剂传递的可电离脂质。

  公开号：

  US20130330401A1
• 作为产物：
  描述：

  ((tert-butoxycarbonyl)azanediyl)bis(ethane-2,1-diyl) ditetradecanoate 在 potassium phosphate 、 dipotassium hydrogenphosphate 、 potassium carbonate 作用下， 以 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 0.17h， 生成 ((2-((2-(dimethylamino)ethyl)thio)-acetyl)azanediyl)bis(ethane-2,1-diyl)ditetradecanoate
  参考文献：
  名称：

  LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS

  摘要：

  该描述针对可用于增强脂质体中治疗剂传递的可电离脂质。

  公开号：

  US20130330401A1

文献信息

• COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY
  申请人：Niitsu Yoshiro

  公开号：US20130017249A1

  公开（公告）日：2013-01-17

  Here described are compounds consisting of the structure (targeting molecule) m -linker-(targeting molecule) n , wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.

  这里描述的是由结构（靶向分子）m-连接物（靶向分子）n组成的化合物，其中靶向分子是一种视黄醇或脂溶性维生素，在靶细胞上具有特定的受体；其中m和n独立地为0、1、2或3；连接物包括聚乙二醇（PEG）或类似PEG的分子，以及包括这些化合物的组合物和药物制剂，用于治疗剂的靶向和传递；以及使用这些组合物和药物制剂的方法。
• CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS
  申请人：Niitsu Yoshiro

  公开号：US20130022665A1

  公开（公告）日：2013-01-24

  Here described are compounds of formula I: wherein R 1 and R 2 is independently selected from a group consisting of C 10 to C 18 alkyl, C 12 to C 18 alkenyl, and oleyl group; wherein R 3 and R 4 are independently selected from a group consisting of C 1 to C 6 alkyl, and C 2 to C 6 alkanol; wherein X is selected from a group consisting of —CH 2 —, —S—, and —O— or absent; wherein Y is selected from —(CH 2 ) n —S(CH 2 ) n , —O(CH 2 ) n —, thiophene, —SO 2 (CH 2 ) n —, and ester, wherein n=1-4; wherein a=1-4; wherein b=1-4; wherein c=1-4; and wherein Z is a counterion; as well as compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents; and methods of using these compositions and formulations.

  本文描述了式I的化合物：其中R1和R2分别选自由C10到C18烷基，C12到C18烯基和油酰基组成的一组；其中R3和R4分别选自由C1到C6烷基和C2到C6烷醇组成的一组；其中X选自由—CH2—，—S—和—O—或不存在的一组；其中Y选自由—（CH2）n—S（CH2）n，—O（CH2）n—，噻吩，—SO2（CH2）n—和酯的一组，其中n=1-4；其中a=1-4；其中b=1-4；其中c=1-4；其中Z是一个带电离子；以及包括式I化合物的组合物和药物制剂，用于传递治疗剂；以及使用这些组合物和制剂的方法。
• DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS
  申请人：Nitto Denko Corporation

  公开号：US20130171240A1

  公开（公告）日：2013-07-04

  Disclosed is a stellate cell-specific drug carrier comprising a stellate cell-specific amount of a retinoid derivative and/or a vitamin A analogue, and a drug carrier component other than the retinoid derivative and/or a vitamin A analogue. Also disclosed in a medicine comprising the stellate cell-specific drug carrier, and a drug in an amount effective for controlling the activity or growth of stellate cells.

  本发明公开了一种星形细胞特异性药物载体，包括星形细胞特异性的视黄酸衍生物和/或维生素A类似物的量，以及除视黄酸衍生物和/或维生素A类似物以外的药物载体组分。同时公开了一种药物，包括星形细胞特异性药物载体和药物，药物的用量有效地控制星形细胞的活动或生长。
• TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST
  申请人：Nitto Denko Corporation

  公开号：US20130210744A1

  公开（公告）日：2013-08-15

  Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid and/or derivative thereof; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anticancer-associated fibroblast composition; and a method for treatment of cancer.

  本发明涉及一种新的治疗剂和癌症的新治疗方法。具体涉及的是：一种针对癌细胞和癌相关成纤维细胞中所选细胞的靶向剂，包括维甲酸和/或其衍生物；一种用于该细胞的物质传递载体，包括靶向剂；一种利用靶向剂或载体的抗癌组合物；一种抗癌相关成纤维细胞组合物；以及一种癌症治疗方法。
• Cationic lipids for therapeutic agent delivery formulations
  申请人：Niitsu Yoshiro

  公开号：US09011903B2

  公开（公告）日：2015-04-21

  Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of —CH2—, —S—, and —O— or absent; wherein Y is selected from —(CH2)n, —S(CH2)n, —O(CH2)n—, thiophene, —SO2(CH2)n—, and ester, wherein n=1-4; wherein a=1-4; wherein b=1-4; wherein c=1-4; and wherein Z is a counterion; as well as compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents; and methods of using these compositions and formulations.

  本文描述了化合物I的公式，其中R1和R2分别选自由C10到C18烷基，C12到C18烯基和油酰基的组；R3和R4分别选自由C1到C6烷基和C2到C6醇的组；X选自由—CH2—，—S—和—O—或缺失的组；Y选自由—（CH2）n，—S（CH2）n，—O（CH2）n—，噻吩，—SO2（CH2）n—和酯的组，其中n = 1-4；a = 1-4；b = 1-4；c = 1-4；Z为反离子；以及包括化合物I的组成物和药物制剂，其对于治疗剂的输送是有用的；以及使用这些组成物和制剂的方法。